Abiopharma

🔍 VON ESCHENBACH ANDREW C. (Executive)

Company: Bausch & Lomb Corp (BLCO)

Report Date: 2026-08-06

Detailed Transactions and Holdings:

• Sold 12,500 shares of Common Shares, No Par Value at $16.5 per share (Direct)
  Date: 2026-08-06 | Code: S | equity_swap_involved: false | shares_owned_after: 69,792.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 6,059 shares of Common Shares, No Par Value at $16.58 per share (Direct)
  Date: 2026-08-07 | Code: S | equity_swap_involved: false | shares_owned_after: 63,733.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.43 to $16.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $16.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F3: Reflects the exempt forfeiture to the Issuer of 4,364 matching restricted share units ("MRSUs") for no consideration in connection with the reporting person's resignation from the Board of Directors of the Issuer on August 5, 2026, in accordance with the terms of such MRSUs.